In addition to tumor mutational burden (TMB) and intrinsic subtypes, RNA-based assays are now available for clinical trials to measure immune cell activity in the tumor microenvironment given a tumor specimen. Our laboratory results suggest measuring immune cell type activity, key variants and mutations, and TMB all have clinical relevance pan-cancer and shape outcomes. Separately, they each provide important information about the tumor and its micro-environment and can often be combined to explain much more than any single factor  individually. Therefore, there are opportunities for employing additional genomic and proteomic biomarkers to predict or explain variation in outcomes when performed by qualified laboratories. In this webcast, we will discuss how Immune landscape signatures, TMB, immune checkpoints, and tumor subtypes are all important measurements in oncology and immunotherapy clinical trials. We will also explore how therapeutic response and key clinical endpoints, such as progression-free and overall survival, are highly associated with key genomic factors such as immune activity and TMB.

Key Learning Objectives:

• Understand different aspects of immune cell activity and their pro and anti-tumor characteristics
• Examine advantages of multi-variable analysis of survival and therapeutic response using clinical and genomic factors and how this can lead to useful biomarkers in many distinct indications
• Demonstrate the empirically measured quantitative relationships pan-cancer between key immune-related components such as cytotoxic T lymphocytes, B cells, macrophages, checkpoints, and TMB in solid tumors

Download our webcast presentation or watch on demand.